



Rothia aeria Infective Endocarditis: a First Case in Korea and Literature Review

Uh-Jin Kim, M.D.¹, Eun Jeong Won, M.D.², Ji-Eun Kim, M.D.¹, Mi-Ok Jang, M.D.¹, Seung-Ji Kang, M.D.¹, Hee-Chang Jang, M.D.¹, Kyung-Hwa Park, M.D.¹, Sook-In Jung, M.D.¹, and Jong-Hee Shin, M.D.²

Departments of Infectious Diseases¹ and Laboratory Medicine², Chonnam National University Medical School, Gwangju, Korea

Rothia species are pleomorphic gram-positive bacteria that belong to the *Micrococcaceae* family [1]. The *Rothia* genus presently comprises 6 named species, 2 of which are deemed clinically relevant: *Rothia dentocariosa* and *Rothia mucilaginosa* [2-6]. Another member of the genus, *Rothia aeria*, a taxon group provisionally named *R. dentocariosa* genomovar II, is a rare cause of human infections [2, 7]. To date, only 6 cases of human infection caused by *R. aeria* have been reported, including bacteremia [8], neck abscesses [9], respiratory tract infection [10, 11], septic arthritis [12], and infective endocarditis [13]. Although *Rothia* species have rarely been reported as a causative pathogen of infective endocarditis, no case has been reported in Korea. Moreover, the risk factors for invasive infection by *R. aeria* are not well defined because of its rarity and the difficulty of correct species identification. Here, we report a case of infective endocarditis caused by *R. aeria* in a patient taking tumor necrosis factor (TNF)- α blocker.

A 53-yr-old Korean man reported fever and chills for 7 days before he visited a nearby clinic and was prescribed an empirical 15-day antibiotic treatment of ceftriaxone and doxycycline. The symptoms improved after antibiotic treatment. However, 10 days after discontinuing treatment, the fever and chills recurred. The patient visited Chonnam National University Hospital (Gwangju, Korea), a 1,000-bed referral center, for further evalu-

ation and treatment. The patient had a history of seropositive ankylosing spondylitis, which had been diagnosed 9 years ago, and had received weekly subcutaneous injections of 25 mg TNF- α blocker (Enbrel; Wyeth, Madison, NJ, USA) for 8 yr. He had also taken 10 mg atorvastatin daily for dyslipidemia. He underwent aortic valvuloplasty, tricuspid valvuloplasty, and a Maze operation owing to severe aortic valve regurgitation with atrial fibrillation 9 yr ago. The patient had also had 4 dental implant placements 2 yr ago. On admission, his vital signs were as follows: blood pressure, 120/80 mmHg; pulse rate, 84 beats/min; respiratory rate, 20/min; and body temperature, 38.2°C. Conjunctival hemorrhage was observed in the right eyelid. A grade 2 early systolic murmur was heard in the third left intercostal space. No Janeway lesions or Osler's nodes were observed. The initial laboratory examination revealed a white blood cell count of $8.1 \times 10^9/L$, hemoglobin of 11.3 g/dL, platelet count of $1.1 \times 10^{11}/L$, and C-reactive protein level of 4.51 mg/dL.

On the day of and a day after admission, 4 sets of blood culture samples were collected in BACTEC Plus Aerobic/F and Anaerobic/F bottles (BD Diagnostics, Sparks, MD, USA) and incubated in an automated blood culture system (BACTEC 9240; BD Diagnostics). Transthoracic echocardiography revealed vegetation measuring 1.35 \times 0.57 cm at the anterior leaflet of the bicuspid aortic valve and an ejection fraction of 56% (Fig. 1).

Received: June 10, 2013

Revision received: November 28, 2013

Accepted: May 1, 2014

Corresponding author: Hee-Chang Jang

Department of Infectious Diseases, Chonnam National University Medical School, 160 Baekseo-ro, Dong-gu, Gwangju 501-746, Korea
Tel: +82-62-220-6296, Fax: +82-62-225-8578
E-mail: haroc153@naver.com

© The Korean Society for Laboratory Medicine.

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (<http://creativecommons.org/licenses/by-nc/3.0>) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.




Fig. 1. Transthoracic echocardiography revealed echoic mobile vegetation (arrowheads) on the anterior leaflet during diastole (A) and on the bicuspid aortic valve during systole (B).




Fig. 2. Microbiological examinations. (A) Dry, coarse white and gray *Rothia aeria* colonies grown on blood agar plates at 35°C and 5% CO₂. (B) *Rothia aeria* Gram staining (×1,000).

Empirical antibiotic therapy with 2 g ceftriaxone every 24 hr was started on the second day of admission. All sets of blood cultures yielded the same pleomorphic filamentous gram-positive branching bacilli, resembling the *Nocardia* species on Gram staining. A pure growth of dry, coarse white and gray colonies was obtained after 48-hr incubation on blood agar plates at 35°C and 5% CO₂ (Fig. 2). The modified Ziehl–Neelsen staining was negative. Biochemical characterization of the isolates was performed using a VITEK 2 GP card (bioMérieux, Mary-l'Étoile, France) and MicroScan Pos Breakpoint Combo panel type 28 (Siemens, Deerfield, IL, USA). The systems identified the microorganism as *Micrococcus luteus/lylae* (99%) and *Micrococcus* spp. (98%), respectively. The microorganism was positive for alanine-phenylalanine-proline arylamidase, L-leucine arylamidase, alanine arylamidase, proline arylamidase, tyrosine arylamidase, L-pyroglutamic acid arylamidase, α -glucosidase, and

esculin hydrolysis. For definitive identification, the 16S rRNA gene was amplified with universal primers (forward: 5'-AGTTT-GATCCTGGCTCAG-3'; reverse: 5'-GTATTGCCGCGGCTGCTG-3') and sequenced. The 830-bp query sequence was 100% homologous to 16S rRNA gene sequences from *R. aeria* (GenBank accession no. AB753461). Antibiotic susceptibility tests were performed by using Etest (BioMérieux) and the disk diffusion method (BD diagnostics). Since no CLSI protocols exist for *R. aeria*, we assessed the organism's drug susceptibility utilizing CLSI criteria for staphylococci (M100-S21) [14], as described previously [8, 10, 13]. The antibiotic susceptibility test results are shown in Table 1.

On the third day of admission, the patient was transferred to Asan Medical Center (Seoul, Korea), where he underwent an aortic valve replacement with an annular reconstruction with bovine pericardium. Pathological examination of heart valve and

aorta tissues revealed bacterial valvulitis and gram-positive coccobacilli. However, no pathogen was grown from these tissues. Direct 16S rRNA gene PCR of these surgical tissues was not performed. Owing to aortic annular destruction, a complete atrioventricular block occurred after surgery, and a permanent pacemaker was implanted 10 days after the operation. The patient received ceftriaxone 2 g every 24 hr for 4 weeks and was then discharged. He regularly visited Chonnam National University Hospital for 4 months without evidence of recurrence.

Up to 85% of infective endocarditis cases are attributed to staphylococci, streptococci, and enterococci. However, clinicians

must be aware of the organisms responsible for the remaining 15% of infective endocarditis [15-17]. Of *Rothia* species, *R. dentocariosa*, a part of the normal community of microbes residing in the oral cavity, has been the most frequent cause of infective endocarditis, with more than 15 reported cases [18]. So far, *R. aeria*, a gram- and catalase-positive bacillus with its branching, filamentous morphology, has been reported as a cause of infective endocarditis in only 1 case [13]. The present case is the second report of *R. aeria* infective endocarditis in the English literature and the first reported case in Korea.

Until now, only 6 cases of invasive *R. aeria* human infections have been reported (Table 2) [8-13]. Of the 6 reported cases of *R. aeria* infection, 4 patients were on immunosuppressive drugs, while 1 was a neonate. These cases suggest that *R. aeria* is an opportunistic pathogen of immunocompromised patients rather than of immunocompetent hosts. The current case also had predisposing risk factors: he was taking an immunosuppressive agent, TNF- α blocker, and had an autoimmune disorder. To date, isolation of *R. aeria* from clinical specimens has seldom been recognized in Korea. Our isolates were initially misidentified as *Micrococcus* spp. by 2 commercial identification systems. *R. dentocariosa* and *R. aeria* share the same biochemical profiles: positive for nitrate reduction, α -glucosidase, alanine-phenylalanine-proline arylamidase, and esculin hydrolysis and negative for urease [2, 7, 19]. The strain in this case also shared common biochemical characteristics with *R. dentocariosa* and *R. aeria*: positive for alanine-phenylalanine-proline arylamidase,

Table 1. Antibiotic susceptibility of *Rothia aeria*

Antibiotics	Susceptibility	MIC ($\mu\text{g/mL}$)*	Inhibition zone diameter (mm) [†]
Penicillin	S	0.012	
Erythromycin	S	0.016	
Gentamycin	S	1.0	
Vancomycin	S	1.0	
Ceftriaxone	S		25
Cefotaxime	S		25
Ciprofloxacin	S		37
Imipenem	S		50
Meropenem	S		27

The drug susceptibility of *Rothia aeria* in the present case was determined by using Etest* or the disk diffusion method[†] according to the 2011 Clinical and Laboratory Standards Institute (M100-S21) criteria for staphylococci. Abbreviations: MIC, minimum inhibitory concentration; S, susceptible.

Table 2. Reported cases of human infection by *Rothia aeria*

Reference	Age (yr)/gender	Underlying disorder	Immunosuppressive medication	Presentation	Antibiotic susceptibility
Present case	53/M	Ankylosing spondylitis, Valvular heart disease	TNF- α blocker	Infective endocarditis	Penicillin (S)* Vancomycin (S)*
[8]	0/F	Maternal tooth extraction	None	Neonatal sepsis	Penicillin (S) [†] Vancomycin (S) [†]
[9]	18/M	X-linked chronic granulomatous disease	Steroids	Neck abscess	Penicillin (S) [‡]
[10]	66/M	Rheumatoid arthritis, Diabetes mellitus	TNF- α blocker	Acute bronchitis	Penicillin (S)* Vancomycin (S)*
[11]	53/F	Neurosarcoidosis	Azathioprine, steroids	Cavitary pneumonia	Penicillin (S) [†] Teicoplanin (S) [†]
[12]	88/F	Rheumatoid arthritis	Methotrexate, steroids	Septic arthritis	Penicillin (S)* Vancomycin (S)*
[13]	40/M	Allergic conjunctivitis	None	Infective endocarditis with cerebral hemorrhage	Penicillin (S)* Vancomycin (I)*

Antibiotic susceptibilities, shown in parentheses as S, I, and R, were determined by using Etest*, the disk diffusion method[†], or MicroScan microdilution[‡], and the Clinical and Laboratory Standards Institute staphylococcal standards.

Abbreviations: M, male; F, female; TNF, tumor necrosis factor; S, susceptible; I, intermediate; R, resistant.

α -glucosidase, and esculin hydrolysis and negative for urease. However, the strain was negative for nitrate reduction. The morphological findings were unlike *Micrococcus* species, which are characterized by gram-positive cocci in a tetrad arrangement; therefore, molecular identification was performed. Sequencing of the 16S rRNA gene enabled an accurate species-level identification of *R. aeria*, which may resemble the *Nocardia* species in Gram staining. These findings suggest that the paucity of isolations of this species from clinical specimens may reflect, in part, the difficulty in identifying this species.

In summary, this is the first case report of infective endocarditis caused by *R. aeria* in Korea, and our case highlights that *R. aeria* should be considered as a rare cause of infective endocarditis, particularly in patients taking immunosuppressive medication. Therefore, as a gram-positive bacillus, *R. aeria* should also be considered a pathogen, and correct species identification and antibiotic susceptibility tests are warranted to ensure the use of appropriate antibiotics.

Authors' Disclosures of Potential Conflicts of Interest

No potential conflicts of interest relevant to this article were reported.

REFERENCES

1. Shin JH, Shim JD, Kim HR, Sinn JB, Kook JK, Lee JN. *Rothia dentocariosa* septicemia without endocarditis in a neonatal infant with meconium aspiration syndrome. *J Clin Microbiol* 2004;42:4891-2.
2. Funke G and Bernard KA. Coryneform Gram-positive rods. In: Versalovic J, Carroll KC, et al. eds. *Manual of clinical microbiology*. 10th ed. Washington DC: ASM Press, 2011:413-42.
3. Ergin C, Sezer MT, Agalar C, Katirci S, Demirdal T, Yayli G. A case of peritonitis due to *Rothia dentocariosa* in a CAPD patient. *Perit Dial Int* 2000;20:242-3.
4. Shakoor S, Fasih N, Jabeen K, Jamil B. *Rothia dentocariosa* endocarditis with mitral valve prolapse: case report and brief review. *Infection* 2011;39:177-9.
5. Cho EJ, Sung H, Park SJ, Kim MN, Lee SO. *Rothia mucilaginosus* pneumonia diagnosed by quantitative cultures and intracellular organisms of bronchoalveolar lavage in a lymphoma patient. *Ann Lab Med* 2013;33:145-9.
6. McWhinney PH, Kibbler CC, Gillespie SH, Patel S, Morrison D, Hoffbrand AV, et al. *Stomatococcus mucilaginosus*: an emerging pathogen in neutropenic patients. *Clin Infect Dis* 1992;14:641-6.
7. Li Y, Kawamura Y, Fujiwara N, Naka T, Liu H, Huang X, et al. *Rothia aeria* sp. nov., *Rhodococcus baikonurensis* sp. nov. and *Arthrobacter ruscicus* sp. nov., isolated from air in the Russian space laboratory Mir. *Int J Syst Evol Microbiol* 2004;54:827-35.
8. Monju A, Shimizu N, Yamamoto M, Oda K, Kawamoto Y, Ohkusu K. First case report of sepsis due to *Rothia aeria* in a neonate. *J Clin Microbiol* 2009;47:1605-6.
9. Falcone EL, Zelazny AM, Holland SM. *Rothia aeria* neck abscess in a patient with chronic granulomatous disease: case report and brief review of the literature. *J Clin Immunol* 2012;32:1400-3.
10. Michon J, Jeulin D, Lang JM, Cattoir V. *Rothia aeria* acute bronchitis: the first reported case. *Infection* 2010;38:335-7.
11. Hiyamuta H, Tsuruta N, Matsuyama T, Satake M, Ohkusu K, Higuchi K. First case report of respiratory infection with *Rothia aeria*. *Nihon Kokyuki Gakkai Zasshi* 2010;48:219-23.
12. Verrall AJ, Robinson PC, Tan CE, Mackie WG, Blackmore TK. *Rothia aeria* as a cause of sepsis in a native joint. *J Clin Microbiol* 2010;48:2648-50.
13. Tarumoto N, Sujino K, Yamaguchi T, Umeyama T, Ohno H, Miyazaki Y, et al. A first report of *Rothia aeria* endocarditis complicated by cerebral hemorrhage. *Intern Med* 2012;51:3295-9.
14. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial susceptibility testing. Twenty-first Informational supplement, M100-S21. Wayne, PA: National Committee for Clinical Laboratory Standards, 2011.
15. Habib G, Hoen B, Tornos P, Thuny F, Prendergast B, Vilacosta I, et al. Guidelines on the prevention, diagnosis, and treatment of infective endocarditis (new version 2009): the Task Force on the Prevention, Diagnosis, and Treatment of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) and the International Society of Chemotherapy (ISC) for Infection and Cancer. *Eur Heart J* 2009;30:2369-413.
16. Lim MH, Chung DR, Kim WS, Park KS, Ki CS, Lee NY, et al. First case of *Bartonella quintana* endocarditis in Korea. *J Korean Med Sci* 2012;27:1433-5.
17. Jang HC, Park WB, Kim HB, Kim EC, Oh MD. Clinical features and rate of infective endocarditis in non-faecalis and non-faecium enterococcal bacteremia. *Chonnam Med J* 2011;47:111-5.
18. Kong R, Mebazaa A, Heitz B, De Briel DA, Kiredjian M, Raskine L, et al. Case of triple endocarditis caused by *Rothia dentocariosa* and results of a survey in France. *J Clin Microbiol* 1998;36:309-10.
19. Ko KS, Lee MY, Park YK, Peck KR, Song JH. Molecular identification of clinical *Rothia* isolates from human patients: proposal of a novel *Rothia* species, *Rothia arfidiae* sp. nov. *J Bacteriol Virol* 2009;39:159-64.